Sirolimus has a potential to influent viral recurrence in HCV positive liver transplant candidates

International Immunopharmacology

Volumn 10, Issue 8, 2010, Pages 990-993

  Wagner, Doris ^a   Kniepeiss, Daniela ^a   Schaffellner, Silvia ^a   Jakoby, Estrella ^a   Mueller, Helmut ^a   Fahrleitner Pammer, Astrid ^a   Stiegler, Philipp ^a   Tscheliessnigg, Karl Heinz ^a   Iberer, Florian ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

HCV recurrence; Liver transplantation; MTOR inhibition; Sirolimus

Indexed keywords

AMINOTRANSFERASE; CALCINEURIN INHIBITOR; RAPAMYCIN; VIRUS RNA;

ADULT; ARTICLE; COHORT ANALYSIS; FEMALE; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPERTRANSAMINASEMIA; IMMUNOSUPPRESSIVE TREATMENT; LIVER GRAFT; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENT DISEASE; RELAPSE; SURVIVAL; VIRUS LOAD;

COHORT STUDIES; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS, VIRAL, HUMAN; HUMANS; LIVER; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RECURRENCE; SIROLIMUS; SURVIVAL ANALYSIS; TRANSAMINASES; VIRAL LOAD; VIRUS ACTIVATION; VIRUS REPLICATION; WAITING LISTS;

EID: 77954951435     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2010.05.006     Document Type: Article

References (19)

1. Charlton M. Hepatitis C infection in liver transplantation. Am J Transplant 2001, 1:197-203.
2. Rakela J., Vargas H.E. Hepatitis C: magnitude of the problem. Liver Transplant 2002, 8(suppl1):S3-S6.
3. Pelletier S.J., Iezzoni J.C., Crabtree T.D., Hahn Y.S., Sawyer R.G., Pruettl T.L. Prediction of liver allograft fibrosis after transplantation for hepatitis C virus: persistent elevation of serum transaminase levels versus necroinflammatory activity. Liver Transplant 2000, 6:44-53.
4. Gane E.J., Portmann B.C., Naoumov N.V., Smith H.M., Underhill J.A., Donaldson P.T., et al. Long term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996, 334:815-820.
5. Shiffman M.L., Vargas H.E., Everson G.T. Controversies in the management of hepatitis C virus infection after liver transplantation. Liver Transplant 2003, 11:1129-1144.
6. Berenguer M., Ferrell L., Watson J., Prieto M., Kim M., Rayon M., et al. HCV-related fibrosis progression after liver transplantation: increase in recent years. J Hepatol 2000, 32:673-684.
7. Gane E.J., Naoumov N.V., Quian K.-P., Mondelli M.U., Maertens G., Portmann B.C., et al. A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology 1996, 110:167-177.
8. Papatheodoridis G.V., Barton S.G.R.G., Andrew G., Clewley G., Davies S., Dhillon AP., et al. Longitudinal variation in Hepatitis C virus (HCV) viremia and early course of HCV infection after liver transplantation for HCV recurrence after liver transplantation for HCV cirrhosis: the role of different immunosuppressive regimens. Gut 1999, 45:427-434.
9. Everson G.T. The impact of immunosuppressive therapy on recurrence of hepatitis C. Liver Transplant 2002, 8(Suppl 1):S19-S27.
10. Coito C., Diamond D.L., Neddermann P., Korth M.J., Katze M.G. High.throughput screening of the yeast kinome: identification of human serine/threonine protein kinases that phosphorylate the hepatitis C virus NS5A protein. J Virol 2004, 48:3502-3513.
11. Mannova P., Beretta L. Activation of the N-Ras-PI3K-Akt-mTOR pathway by hepatitis C virus: control of cell survival and viral replication. J Virol 2005, 79:8742-8749.
12. Kniepeiss D., Iberer F., Grasser B., Schaffellner S., Stadlbauer V., Tscheliessnigg K.H. A single center experience with retrograde reperfusion in liver transplantation. Transpl Int 2003, 16:730-735.
13. Ishak K.G. Pathologic features of chronic hepatitis. Am J Clin Pathol 2000, 113:40-55.
14. Forman L.M., Lewis J.D., Berlin J.A., Feldman H.I., Lucey M.R. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002, 122:889-896.
15. Sánchez-Fueyo A., Restrepo J.C., Quintó L., Bruguera M, Grande L., Sánchez-Tapias J.M., et al. Impact of the recurrence of hepatitis C virus infection after liver transplantation on the long-term viability of the graft. Transplantation 2002 Jan 15, 73(1):56-63.
16. Sheiner P.A., Schwartz M.E., Mor E., Schluger L.K., Theise N., Kishikawa K., et al. Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. Hepatology 1995, 21:30-34.
17. European FK506 Multicenter Liver Study Group A comparison of tacrolimus (FK506) and cyclosporine in prevention of liver allograft rejection. Lancet 1994, 331:1110-1115.
18. Mueller A., Platz K., Bechstein W.O., Fukomoto T, Guckelberger O, Neuhaus R., et al. Increased rejection after liver transplantation FK506- treated patients is associated with viral hepatitis C disease. Transplant Proc 1994, 26:3637-3639.
19. Trotter JF Sirolimus in liver transplantation. Transplantation Proceedings 2003, 35(3A):193S-200S.